HomeCompareMDRX vs QYLD

MDRX vs QYLD: Dividend Comparison 2026

MDRX yields 43.01% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MDRX wins by $247.4K in total portfolio value
10 years
MDRX
MDRX
● Live price
43.01%
Share price
$4.65
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$272.8K
Annual income
$48,949.82
Full MDRX calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — MDRX vs QYLD

📍 MDRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMDRXQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MDRX + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MDRX pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MDRX
Annual income on $10K today (after 15% tax)
$3,655.91/yr
After 10yr DRIP, annual income (after tax)
$41,607.35/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, MDRX beats the other by $36,796.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MDRX + QYLD for your $10,000?

MDRX: 50%QYLD: 50%
100% QYLD50/50100% MDRX
Portfolio after 10yr
$149.1K
Annual income
$27,304.57/yr
Blended yield
18.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MDRX right now

MDRX
Analyst Ratings
1
Strong
15
Buy
23
Hold
3
Sell
1
Strong
Consensus: Hold
Price Target
$16.17
+247.7% upside vs current
Range: $10.00 — $20.00
Altman Z
2.7
Piotroski
5/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MDRX buys
0
QYLD buys
0
No recent congressional trades found for MDRX or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMDRXQYLD
Forward yield43.01%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$272.8K$25.4K
Annual income after 10y$48,949.82$5,659.31
Total dividends collected$209.5K$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: MDRX vs QYLD ($10,000, DRIP)

YearMDRX PortfolioMDRX Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$15,001$4,301.08$10,352$1,192.36+$4.6KMDRX
2$22,081$6,029.98$10,830$1,347.57+$11.3KMDRX
3$31,922$8,295.27$11,460$1,539.07+$20.5KMDRX
4$45,364$11,207.71$12,275$1,777.84+$33.1KMDRX
5$63,425$14,885.26$13,323$2,078.95+$50.1KMDRX
6$87,315$19,449.99$14,667$2,463.34+$72.6KMDRX
7$118,451$25,024.33$16,396$2,960.57+$102.1KMDRX
8$158,470$31,727.08$18,631$3,612.97+$139.8KMDRX
9$209,232$39,669.21$21,548$4,482.15+$187.7KMDRX
10$272,828$48,949.82$25,398$5,659.31+$247.4KMDRX

MDRX vs QYLD: Complete Analysis 2026

MDRXStock

Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising Practice Management software, AI Patient Scheduling Software, and Electronic Statements and Payments; revenue cycle management solutions, including Revenue Cycle Services and revenue cycle management clearinghouse; electronic health records solutions, which include ePrescribe with EPCS, EHR software, Veradigm HER, and Practice Fusion HER; and Patient Engagement Platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as Veradigm Connect, Veradigm App Expo, and Diagnostic Ordering and Resulting Network; Channel Partner Program; and Veradigm ePrescribe Enterprise. In addition, the company offers solutions to health plans and payers, comprising risk adjustment solutions, such as Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics; quality management solutions, which include quality analytics and risk adjustment and quality management; data exchange+coding solutions, including eChart Courier, eChart Coder, and eChart Integration and Analytics; provider engagement and Veradigm Payer Insights; and Veradigm Payerpath solutions. Further, it provides solutions to biophama, including real world data solutions, such as real world and health data sets and cardiology and metabolic registries; real world evidence and Real World Evidence Analytics Platform; therapy focused solutions, such as cardiovascular, central nervous system, metabolic, and immunology data; and Digital Health Media solutions. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

Full MDRX Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this MDRX vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MDRX vs SCHDMDRX vs JEPIMDRX vs OMDRX vs KOMDRX vs MAINMDRX vs XYLDMDRX vs JEPQMDRX vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.